Genentech pays Alector $100M for preclinical Parkinson’s prospect
Genentech’s $100 million upfront for Alector’s preclinical Parkinson’s candidate ignites a multi‑billion licensing race.
Evidence dossier
Intelligence passport
Measured timeline
Momentum
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Where it stands
- Velocity & Diffusion: Coverage exploded across 5 distinct news outlets with 5 published articles, achieving a live velocity of 14.
- Primary Driver: Genentech’s $100 million upfront for Alector’s preclinical Parkinson’s candidate ignites a multi‑billion licensing race.
- Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.
Reuters later disclosed that the agreement includes potential payouts up to $1.27 billion, while Yahoo Finance detailed a global license for a brain‑penetrant GCase enzyme replacement aimed at Parkinson’s and other neurodegenerative diseases. Stock Titan added that the deal could generate as much as $1.17 billion for Alector if future milestones are achieved.
The only notable inconsistency lies in the maximum valuation: Reuters cites $1.27 billion, whereas Stock Titan references $1.17 billion. Both agree on the $100 million upfront and the focus on a GCase‑based therapy.
The transaction stands with the initial cash payment made, and further milestone payments will depend on the progression of the preclinical program.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (83% supported) Updated 1h ago.
Who reported it (5)
-
Biotech Brainiacs and BreakthroughsWBOC TV · 5h ago
-
-
-
Alector soars as Roche licenses Parkinson's therapy for up to $1.27 billionreuters.com · 5h ago
-
Genentech pays Alector $100M for preclinical Parkinson’s prospectFierce Biotech · 5h ago
Answered
What is the upfront payment in the Genentech‑Alector agreement?
Genentech is paying Alector $100 million up front for the preclinical Parkinson’s prospect.
What type of therapy is covered by the license?
The license covers a brain‑penetrant GCase enzyme replacement therapy intended for Parkinson’s disease and other neurodegenerative conditions.
How much could Alector earn if development milestones are met?
Potential milestone payments could bring total value to up to $1.27 billion according to Reuters, or up to $1.17 billion as noted by Stock Titan.
How do you expect this trend to evolve over the next 24 hours?
Cast your vote to register reader intelligence on the velocity and trajectory of this coverage.
Topics
Related trends
Alan Alda on fighting Parkinson's with laughter
Actor opens up about Parkinson's diagnosis and management
Prion-like transmission of human tau strains in the mouse brain
Tau proteins in the human brain may behave like infectious agents, spreading disease in mice.
Roche Halts Development of Obesity Drug Candidate
Roche’s sudden halt of its muscle‑sparing obesity antibody reverberates through patients, investors and the biotech pipeline.
AbbVie's Cerevel buyout delivers as FDA gives go-ahead to 1st-in-class Juvmo in Parkinson's disease
6 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
New Parkinson’s drug approved in the US: What does it do differently?
AbbVie’s first‑in‑class Parkinson’s pill JUVMO lands FDA approval, yet insiders warn sales will crawl despite a $8.7 billion buyout.
The way your belly button smells could be an early warning sign of Parkinson’s
Belly button odour may signal early warning of Parkinson’s
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.